Phoenix Nest is a niche biotech company based in New York, NY, dedicated to developing treatments for Sanfilippo syndrome, an ultra-rare and untreatable disease. Founded by parents of children with Sanfilippo syndrome type C, the company's management team, supported by grants from the National Institute of Health, is committed to bringing a curative treatment to market and improving the lives of affected families.
With a sense of urgency and unwavering determination, Phoenix Nest has successfully pioneered treatments for these challenging diseases, collaborating with academic labs and licensing research programs. Guided by an Independent Scientific Advisory Board and Board of Directors, the company strives to provide hope and support to parents who tirelessly care for their children, while working towards a future where affected individuals can lead full and happy lives outside the confines of their medical needs.
Generated from the website